26.44
-0.72 (-2.63%)
| 前收盘价格 | 27.15 |
| 成交量 | 585,282 |
| 预期市盈率 (P/E Forward) | 20.58 |
| 价格/销量 (P/S) | 54.63 |
| 股市价格/股市净资产 (P/B) | 24.16 |
| 52周波幅 |
| 营业毛利率 | -121.73% |
| 营业利益率 (TTM) | -94.48% |
| 稀释每股收益 (EPS TTM) | -1.50 |
| 季度收入增长率 (YOY) | 170.30% |
| 总债务/股东权益 (D/E MRQ) | 5.68% |
| 流动比率 (MRQ) | 4.71 |
| 营业现金流 (OCF TTM) | -75.78 M |
| 杠杆自由现金流 (LFCF TTM) | -21.20 M |
| 资产报酬率 (ROA TTM) | -13.89% |
| 股东权益报酬率 (ROE TTM) | -29.80% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Zymeworks Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.5 |
| 平均 | -0.33 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.15% |
| 机构持股比例 | 102.76% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ecor1 Capital, Llc | 30 Jun 2026 | 22,970,388 |
| Perceptive Advisors Llc | 30 Jun 2026 | 4,182,953 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合